Mar 09, 2022 / 04:10PM GMT
Stephen Michael Scala - Cowen and Company, LLC, Research Division - MD & Senior Research Analyst
Well, good morning, and welcome to the Sanofi session of Cowen's 42nd Annual Healthcare Conference. We're very pleased to have Sanofi back again with us this year. Representing the company, Dietmar Berger, who is Chief Medical Officer.
For those clients who have been participating in the conference all week, you've already heard a lot of positive mentions on Sanofi, on the derm panel, the commentary on Dupixent probably could not have been more positive. On the breast cancer panel, the KOLs predicted the amcenestrant Phase II trial, AMEERA-3 will achieve its endpoint, and it will be a fully competitive molecule. And on the nonmalignant heme panel, the KOL spoke about BIVV001 as having a very desirable and competitive profile.
Also, I should note that Sanofi will be having an immunology event on March 29 that will be live in Boston. So that will be another opportunity to learn about Sanofi's broad and deep pipeline. So Dietmar, thank you so much for being with us at our event.
Sanofi SA at Cowen Health Care Conference (Virtual) Transcript
Feb 09, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers